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Objectives: The prevalence of urinary incontinence (UI) in women in Slovakia is 
about 240 000 cases and has an increasing trend. Only 5 % of them were diagnosed 
by visiting urology or gynecology outpatient department. The objective of this paper 
was to find out the level of QoL in women with UI in Slovakia. MethOds: The 
primary method used for the analysis of QoL was the combined questionnaire 
consisting of 6 parts: A. Demography (9 items), B. Clinical part (B1- International 
Consultation on Incontinence (ICIQ-SF): 4 items, B2- characteristics of UI: 23 items), 
C. Quality of life with dominant numeric scale (13 items), D. Socio-economic part (9 
items), E. EQ-5D (5 items), F. Symptoms of disease (9 items). There were 112 patients 
in the examined group from the160 asked to fill the questionnaire. The average age 
was 61 years. Results: Present level of QoL was identified as 6,60 on the scale from 
1 to 10 (1- the worst,10 –the best), while in the time of the UI diagnosis it was 5,10. 
QoL was 8,10 in the time without UI and 9,40 in the total optimal state of health. 
Comparative to the QoL was examined the ability to work (AW), too. Present level 
of AW was identified as 6,50, while in the time of the BC diagnosis it was 5,50. AW 
was 8.20 in the time without UI and 9,40 in the total optimal state of health. The 
impact of treatment on QoL was 7,60 and the disease had impact 7,40 on family 
QoL. The average income was 465,04 € and the willingness to pay for 1 month of 
complete health was in average 391,06 € . cOnclusiOns: The disease had a sig-
nificant impact on patients´s QoL. The treatment of UI had a significant impact on 
increasing QoL of patients.
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Objectives: The purpose of the study is to investigate how the QOL of parents 
whose child had received pediatric kidney tranplantation(KT) would change by 
delivering questionnaires for four times a year. MethOds: The QOL of thirty-one 
parents with a mean age of 38.5 yrs old (30 mothers, 1 father) whose child received 
KT at Toho Ohmori Hospital in Tokyo from May 2012 to March 2015 was measured 
using WHOQOL, GHQ, and VAS for four times; before, one month, three months, 
one year after KT. The mean age of receipient patients was 5.8 yrs old (18 boys, 13 
girls). Congenital anomalies of the kidney and urinary tract were most frequent 
primary diseases. Among them twenty-two children received dialysis before KT, 
and nine received preemtive KT. Results: Based on the results of WHOQOL, the 
QOL of parents dropped with a statistical difference one month after KT, compared 
with before KT (p= 0.042), but rose at three months (p= 0.0073), and maintained 
until one year. The QOL of parents with child with frequent infections was statisti-
cally lower than those without any infectionat three months after KT (p= 0.448) 
and one year after KT (P= 0.0406). The QOL scores of nineteen donor parents had a 
statistically higher QOL before KT, but reversed at one month after KT particurally 
in physical domain of WHOQOL, but became higher again at three month after 
KT, compared with the rest of parents. cOnclusiOns: The QOL of the parents 
would change in the process recovery of child, and with infection or other medi-
cal problems occurred, QOL reflected it, but three months after KT, QOL rose as 
high as before KT.
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Objectives: Nocturia is defined by the International Continence Society as 
the need to void one or more times during the night, with each of the voids 
preceded and followed by sleep. The chronic sleep disturbance and sleep depri-
vation suffered by nocturia patients impacts their entire health-related quality 
of life, compromising both mental and physical well-being. This review aims 
to better characterise the societal burden of nocturia by comparing published 
data from nocturia patients with those of 12 other common chronic conditions, 
specifically focussing on the impact on work productivity and activity impair-
ment, as measured by the WPAI (Work Productivity and Activity Impairment) 
instrument. MethOds: Systematic searches of Medline and the WPAI database 
returned 241 publications, after removal of duplicates, 178 publications were 
screened, and 79 evaluable studies were identified for inclusion in the review. 
Most exclusions were due to duplicate publication of the same study or insuf-
ficient WPAI data presented. Data extraction recorded study and summary-level 
patient characteristics and all reported WPAI data on overall work productiv-
ity impairment and overall activity impairment. Results: The number of 
evaluable studies, the number of different disease-specific subgroups with 
WPAI data and the range of overall work productivity impairment reported, 
respectively, were as follows: nocturia (3, 10, 14-39%); overactive bladder (6, 6, 
11-41%); irritable bowel syndrome/ constipation (11, 13, 25-40%); GERD (13, 15, 
13-33%); asthma/ allergies (11, 15, 6-40%); COPD (7, 9, 21-42%); sleep problems (2, 
3, 12-37%); arthritis (12, 16, 21-69%); pain (8, 9, 29-52%); depression (4, 5, 15-43%); 
and gout (2, 2, 20-37%). cOnclusiOns: The overall work productivity impair-
ment of nocturia is substantial and found to be similar to several other more 
frequently researched common chronic diseases. Greater awareness of the bur-
den of nocturia, a highly bothersome and prevalent condition, will help policy-
makers and healthcare decision-makers to provide appropriate management of 
nocturia.
‘waking to void 1 or more times a night followed by sleep’, is reported as being the 
most bothersome of these symptoms. The most frequent cause of nocturia is noctur-
nal polyuria (NP, overproduction of urine during the night defined as ≥ 33% of total 
urine volume). While there are well-known negative effects of nocturia on Health-
related Quality of Life, there is limited information on the relationship between NP 
disease severity, as defined by the number of nightly voids, and utility. MethOds: 
Data were drawn from a randomised clinical trial of desmopressin (an antidiuretic) 
combined with tolterodine (an antimuscarinic agent) in women with overactive 
bladder and nocturia (ClinTrials.gov identifier: NCT01729819). Patients were required 
to have 2 or more nightly voids to be included in the trial, as this has been shown 
to be a clinically-relevant threshold for patient bother. We selected the subgroup 
of patients with NP who completed the Nocturia Impact Diary (a disease-specific 
HRQoL instrument, ranging from 0-100 where low values imply better QoL) and 
the generic EQ-5D-5L (n= 41). The utility analysis was adjusted for age, body mass 
index, baseline number of nightly voids and number of comorbidities. Results: The 
adjusted mean EQ-5D index for 2-3 voids was 0.87 and for 4 or more nightly voids 
0.83 (ns). The adjusted EQ-5D VAS values were similar at 80.5 and 80.6. Unadjusted 
index utility values were 0.88 and 0.81, respectively. The Nocturia Impact Diary total 
scores were 41.5 and 46.8 for the two groups, respectively. cOnclusiOns: The gen-
eral disadvantage of the EQ-5D is that it is relatively insensitive to urinary diseases. 
This analysis suggests, however, that there is a relationship between nocturnal 
polyuria (and nocturia) disease severity, HRQoL and utility.
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Objectives: To confirm the factor structure and evaluate the reliability, validity, 
and responsiveness of the OAB-q in medically complex elderly with overactive 
bladder (OAB). MethOds: Post-hoc analyses were conducted using data from a 
12-week clinical trial for urgency urinary incontinence (UUI; N= 566). Structure of 
the OAB-q was evaluated using a confirmatory factor analysis. Cronbach’s coef-
ficient alpha (CCA) was used to assess reliability. Convergent validity was exam-
ined using Pearson’s and Spearmen Product-Moment correlations. Known-groups 
validity was assessed by evaluating differences in OAB-q scores in patients cat-
egorized according to UUI severity (mild, moderate, severe) and Patient Perception 
of Bladder Condition (PPBC) severity (Some Moderate Problems, Severe to Many 
Severe Problems). Effect size was used to examine responsiveness of the OAB-q, 
and an anchor-based approach was used to estimate the clinically important dif-
ference. Results: Participants were mainly female (82.2%) and white (85.9%) with 
a mean age of 75.0 (± 6.4) years. Bentler’s Comparative Fit Index was satisfactory 
(0.90), path coefficients were statistically significant (t-values > 1.96), and all stand-
ardized path coefficients were > 0.40, indicating that a second-order measurement 
model with 5 domains and one aggregated domain holds true in the medically com-
plex elderly population. OAB-q domains demonstrated good internal consistency 
(CCAs > 0.7). Convergent validity was supported by moderate correlations (0.4 – 0.7) 
between OAB-q domains and other related patient-reported outcomes. Significant 
differences in OAB-q domain scores between groups of different severity based on 
UUI and PPBC provided evidence of known-groups validity. Responsiveness was 
demonstrated by statistically significant and clinically relevant differences in mean 
scores for the OAB-q domains over time between Baseline and Week 12 with effect 
sizes of those differences of about 0.2. cOnclusiOns: The OAB-q has reliability, 
sound concurrent and discriminative validity with other measures, responsiveness 
to treatment, and is fit for purpose in medically complex elderly patients with OAB.
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Objectives: ADPKD imposes substantial burdens on HRQoL at all stages of the dis-
ease. Few studies have examined disease impacts and symptomatology on HRQoL. 
This analysis aimed to assess whether disease-specific questionnaires allow for 
improved assessment of HRQoL in ADPKD. MethOds: In a large global observa-
tional study of 3,409 subjects, patient-reported outcomes (PRO) instruments (includ-
ing SF-12v2, EQ-5D, ADPKD-IS) were completed in 6-month intervals. Scores were 
calculated at Baseline and longitudinally, overall and by chronic kidney disease 
(CKD) stage. Results: The overall population scores were normal/near normal 
regardless of instrument with little change overtime (mean score at Baseline and 
18 months): SF-12 Mental Component Summary score (MCS) 50.15 to 49.77, SF-12 
Physical Component Summary score (PCS) 49.94 to 49.12; EQ-5D US Index 0.91 to 
0.90; ADPKD-IS Physical 1.59 to 1.66, Emotional 1.78 to 1.79, Fatigue 1.90 to 1.95. 
Only the SF-12 PCS and ADPKD-IS instruments were able to differentiate between 
early and late stage disease at Baseline (CKD1 vs CKD4 at baseline (SD): PCS 52.22 
(8.41) vs 46.79 (9.89), MCS 49.66 (9.90) vs 51.09 (9.63), EQ-5D US Index 1.06 (0.25) 
vs 1.13 (0.34), ADPKD-IS Physical 1.47 (0.82) vs 1.83 (0.88), Emotional 1.72 (0.88) vs 
2.07 (0.91), Fatigue 1.77 (1.03) vs 2.25 (1.23)). Longitudinal changes (Baseline and 18 
months) could only be measured in later disease stages. Changes in EQ-5D and 
SF-12 were driven by impacts on overall health state. cOnclusiOns: The disease-
specific ADPKD-IS questionnaire was more sensitive to HRQoL in a cross-sectional 
analysis by disease severity vs all generic HRQoL instruments except SF-12 PCS. 
In a slowly progressing disease like ADPKD, observations of longitudinal change 
in HRQoL will require longer follow-up. These results support that ADPKD disease 
impacts are incapable of being measured by blunt generic tools.
